Primary hyperparathyroidism: A current perspective

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 8, 2008, Pages 1251-1262

  DeLellis, Ronald A ^a,b   Mazzaglia, Peter ^a   Mangray, Shamlal ^a  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 123; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARAFIBROMIN; PARATHYROID HORMONE; PROTEIN;

CANCER DIAGNOSIS; DIAGNOSTIC IMAGING; FAMILIAL DISEASE; GENE MUTATION; HORMONE DETERMINATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAOPERATIVE PERIOD; MULTIPLE ENDOCRINE NEOPLASIA; NECK TUMOR; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PREOPERATIVE EVALUATION; PRIMARY HYPERPARATHYROIDISM; PROTEIN EXPRESSION; RADIODIAGNOSIS; REVIEW; SIPPLE SYNDROME; SURGICAL APPROACH; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR SCINTISCANNING; ULTRASOUND;

ADENOMA; CARCINOMA; HUMANS; HYPERPARATHYROIDISM, PRIMARY; HYPERPLASIA; INCIDENCE; PARATHYROID GLANDS; PARATHYROID NEOPLASMS; SYNDROME;

EID: 49449093792     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Bringhurst FR, DeMay MB, Kronenberg HM. Hormones and disorders of mineral metabolism In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology. 10th ed. Philadelphia, Pa: Saunders; 2003:1303-1372.
2. Melton LJ. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res. 2002;17:N12-N17.
3. Heath H III, Hodgson SF, Kennedy MA. Primary hyperparathyroidism: incidence, morbidity and potential economic impact in a community. N Engl J Med. 1980;302:189-193.
4. Wermers RA, Khosla S, Atkinson EJ, et al. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med. 1997;126:433-440.
5. Wermers RA, Khosla S, Atkinson EJ, Hodgson SF, O'Fallon WM, Melton LJ III. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21:171-177.
6. Beard CM, Heath H III, O'Fallon W, Anderson JA, Earle JD, Melton LJ III. Therapeutic radiation and hyperparathyroidism: a case control study in Rochester, Minn. Arch Intern Med. 1989;149:1887-1890.
7. Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med. 1990;323:1324-1328.
8. Van Houten JN, Yu N, Rimm D, et al. Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endocrinol Metab. 2006;91:580-583.
9. Molinari AS, Irvin GL III, Deriso GT, Bott L. Incidence of multiglandular disease in primary hyperparathyroidism determined by parathyroid hormone secretion. Surgery. 1996;120:934-936.
10. Grimelius L, DeLellis RA, Bondeson L, et al. Parathyroid adenoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004:128-132. World Health Organization Classification of Tumours.
11. Guiter G, DeLellis RA. Parathyroid glands. In: Silverberg SG, DeLellis RA, Frable WJ, LiVolsi VA, Wick MR, eds. Silverberg; Principles and Practice of Surgical Pathology and Cytopathology. 4th ed. Philadelphia, Pa: Churchill Livingstone Elsevier; 2006:2149-2168.
12. DeLellis RA. Tumors of the Parathyroid Gland. Washington, DC: Armed Forces Institute of Pathology; 1993. Atlas of Tumor Pathology; 3rd series, fascicle 6.
13. Snover D, Foucar K. Mitotic activity in benign parathyroid disease. Am J Clin Pathol. 1981;75:345-347.
14. Abbona GC, Papotti M, Gasparri G, Bussolati G. Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol. 1995;26:135-138.
15. Arnold A, Shattuck TM, Mallya SM, et al. Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res. 2002;17:N30-N36.
16. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Mini reviews: cyclin D1: normal and abnormal functions. Endocrinology. 2004;145:5439-5447.
17. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276:3404-3407.
18. Lemmens I, Van de Ven WJ, Kas K, et al, The European Consortium on MEN1. Identification of the multiple endocrine neoplasia type1 (MEN1) gene. Hum Mol Genet. 1997;6:1177-1183.
19. Agarwal SK, Guru SC, Heppner C, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell. 1999;96:143-152.
20. Agarwal SK, Lee Burns A, Sukhodolets KE, et al. Molecular pathology of the MEN2 gene. Ann N Y Acad Sci. 2004;1014:189-198.
21. Friedman E, Sakaguchi K, Bale AE, et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type1. N Engl J Med. 1989;321:213-218.
22. Imanishi Y. Molecular pathogenesis of tumorigenesis in sporadic parathyroid adenomas. J Bone Miner Metab. 2002;20:190-195.
23. Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RS, Arnold A. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab. 1998;83:1766-1770.
24. Marx SJ, Simonds WF, Agarwal SK, et al. Hyperparathyroidism in hereditary syndromes: special expressions and special management. J Bone Miner Res. 2002;17(suppl 2):N37-N43.
25. Marx S, Spiegel AM, Skarulis M, Doppman JL, Collins FS, Liota LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998;129:434-494.
26. Calender A, Morrison CS, Komminoth P, Skoazec JY, Sweet KM, Teh BT. Multiple endocrine neoplasia type 1. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004:218-227. World Health Organization Classification of Tumours.
27. Gimm O, Morrison CD, Suster S, Komminoth P, Mulligan L, Sweet KM. Multiple endocrine neoplasia type 2. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004:211-217. World Health Organization Classification of Tumours.
28. Thakker RV. Diseases associated with the extracellular calcium-sensing receptor. Cell Calcium. 2004;35:275-282.
29. Chen JD, Morrison C, Zhang C, Kahnoski K, Carpten JD, Teh BT. Hyperparathyroidism-jaw tumor syndrome. J Intern Med. 2003;253:634-642.
30. Teh BT, Sweet KM, Morrison CD. Hyperparathyroidism-jaw tumour syndrome. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004:228-229. World Health Organization Classification of Tumours.
31. Mallette LE, Malini S, Rappaport MP, Kirkland JL. Familial cystic parathyroid adenomatosis. Ann Intern Med. 1987;107:54-60.
32. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2 encoding parafibromin is mutated in hyperparathyroidism jaw tumor syndrome. Nat Genet. 2002;32:676-680.
33. Simonds WF, James-Newton O, Agarwal AK, et al. Familial isolated hyperparathyroidism: clinical and genetic characterizations of 36 kindreds. Medicine. 2002;81:1-26.
34. Warner J, Epstein M, Sweet A, et al. Genetic testing in familial isolated hyperparathyroidism. J Med Genet. 2004;41:155-160.
35. Carling T, Szabo E, Bai M, et al. Familial hypercalcemia and hypercalcuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab. 2000;85:2042-2047.
36. Bondeson L, Grimeluis L, DeLellis RA, et al. Parathyroid carcinoma In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004:124-127. World Health Organization Classification of Tumours.
37. DeLellis RA. Parathyroid carcinoma. Adv Anat Pathol. 2004;12:53-61.
38. Lloyd RV, Carney JH, Ferreiro JA, et al. Immunohistochemical analysis of the cell cycle associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinoma and adenomas. Endocr Pathol. 1995;6:279-287.
39. kip1 protein. Am J Surg Pathol. 1999;23:288-295.
40. Kytola S, Farnebo F, Obara T, et al. Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol. 2000;157:579-586.
41. Erickson LA, Jalal SM, Harwood A, Shearer B, Jin L, Lloyd RV. Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization. Am J Surg Pathol. 2004;28:578-584.
42. Haven CJ, van Puijenbroek M, Karperien M, Fleuren GJ, Morreau H. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1 p and 11q in parathyroid carcinoma. J Pathol. 2004;202:86-94.
43. Valimaki S, Forsberg L, Farnebo LO, Larsson C. Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas. Int J Oncol. 2002;21:727-735.
44. Cryns VL, Thor A, Xu HJ. Loss of the retinoblastoma tumor suppressor gene in parathyroid carcinoma. N Engl J Med. 1994;330:757-761.
45. Pearce SH, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility BRCA2 loci in pituitary, parathyroid, pancreatic and carcinoid tumors. Clin Endocrinol (Oxf). 1996;45:195-200.
46. Cetani F, Pardi E, Viacava P, et al. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid carcinoma. Clin Endocrinol (Oxf). 2004;60:99-106.
47. Shattuck TM, Kim TS, Costa J, et al. Mutational analyses of RB and BRCA2 as candidate tumor suppressor genes in parathyroid carcinomas. Clin Endocrinol (Oxf). 2003;59:180-189.
48. Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumors. J Med Genet. 2003;40:657-663.
49. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germline mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349:1722-1729.
50. Tan MH, Morrison C, Wang P, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res. 2004;10:6629-6637.
51. Gill AJ, Clarkson A, Gimm O, et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor associated adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol. 2006;30:1140-1149.
52. Juhlin C, Larsson C, Yakoleva T, et al. Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr Relat Cancer. 2006;13:509-523.
53. Guiter GE, DeLellis RA. Risk of recurrence or metastasis in atypical parathyroid adenomas [abstract]. Mod Pathol. 2002;15:115A.
54. Stojadinovic A, Hoos A, Nissan A, et al. Parathyroid neoplasms: clinical, histopathological and tissue microarray-based molecular analysis. Hum Pathol. 2003;34:54-64.
55. Bilezikian JP, Potts JT Jr, Fulheihan Gel-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab. 2002;87:5353-5361.
56. Clark OH, Wilkes W, Siperstein AE, Duh OY. Diagnosis and management of asymptomatic hyperparathyroidism: safety, efficacy, and deficiencies in our knowledge. J Bone Miner Res. 1991;6(suppl 2):135-142.
57. Pasieka JL, Parsons LL. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg. 1998;22:513-518.
58. Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). J Nucl Med. 1992;33:1801-1807.
59. Sharma J, Mazzaglia P, Milas M, et al. Radionuclide imaging for hyperparathyroidism (HPT): which is the best technetium-99m sestamibi modality? Surgery. 2006;140:856-863.
60. Krausz Y, Lebensart PD, Klein M, et al. Preoperative localization of parathyroid adenoma in patients with concomitant thyroid nodular disease. World J Surg. 2000;24:1573-1578.
61. Light VL, McHenry CR, Jarjoura D, Sodee DB, Miron SD. Prospective comparison of dual-phase technetium-99m-sestamibi scintigraphy and high resolution ultrasonography in the evaluation of abnormal parathyroid glands. Am Surg. 1996;62:562-567.
62. McHenry CR, Lee K, Saadey J, Neumann DR, Esselstyn CB. Parathyroid localization with technetium-99m-sestamibi: a prospective evaluation. J Am Coll Surg. 1996;183:25-30.
63. Bhansali A, Masoodi SR, Bhadada S, Mittal BR, Behra A, Singh P. Ultrasonography in detection of single and multiple abnormal parathyroid glands in primary hyperparathyroidism: comparison with radionuclide scintigraphy and surgery. Clin Endocrinol (Oxf). 2006;65:340-345.
64. Haber RS, Kim CK, Inabnet WB. Ultrasonography for preoperative localization of enlarged parathyroid glands in primary hyperparathyroidism: comparison with (99m) technetium sestamibi scintigraphy. Clin Endocrinol (Oxf). 2002;57:241-249.
65. Lo CY, Lang BH, Chan WF, Kung AW, Lam KS. A prospective evaluation of preoperative localization by technetium-99m sestamibi scintigraphy and ultrasonography in primary hyperparathyroidism. Am J Surg. 2007;193:155-159.
66. Solorzano CC, Carneiro-Pla DM, Irvin GL III. Surgeon-performed ultrasonography as the initial and only localizing study in sporadic primary hyperparathyroidism. J Am Coll Surg. 2006;202:18-24.
67. Irvin GL III, Dembrow VD, Prudhomme DL. Operative monitoring of parathyroid gland hyperfunction. Am J Surg. 1991;162:299-302.
68. Irvin GL III, Dembrow VD, Prudhomme DL. Clinical usefulness of an intraoperative "quick parathyroid hormone" assay. Surgery. 1993;114:1019-1022.
69. Garner SC, Leight GS Jr. Initial experience with intraoperative PTH determinations in the surgical management of 130 consecutive cases of primary hyperparathyroidism. Surgery. 1999;126:1132-1137.
70. Vignali E, Picone A, Materazzi G, et al. A quick intraoperative parathyroid hormone assay in the surgical management of patients with primary hyperparathyroidism: a study of 206 consecutive cases. Eur J Endocrinol. 2002;146:783-788.
71. Westerdahl J, Bergenfelz A. Sestamibi scan-directed parathyroid surgery: potentially high failure rate without measurement of intraoperative parathyroid hormone. World J Surg. 2004;28:1132-1138.
72. Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg. 2002;235:665-670.
73. Siperstein A, Berber E, Mackey R, Alghoul M, Wagner K, Milas M. Prospective evaluation of sestamibi scan, ultrasonography, and rapid PTH to predict the success of limited exploration for sporadic primary hyperparathyroidism. Surgery. 2004;136:872-880.
74. Cope O. The study of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med. 1966;274:1174-1182.
75. Thompson NW, Eckhauser FE, Harness JK. The anatomy of primary hyperparathyroidism. Surgery. 1982;92:814-821.
76. Low RA, Katz AD. Parathyroidectomy via bilateral cervical exploration: a retrospective review of 866 cases. Head Neck. 1998;20:583-587.
77. Proye CA, Carnaille B, Bizard JP, Quievreux JL, LeComte-Houcke M. Multiglandular disease in seemingly sporadic primary hyperparathyroidism revisited: where are we in the early 1990s? A plea against unilateral parathyroid exploration. Surgery. 1992;112:1118-1122.
78. Carneiro DM, Solorzano CC, Irvin GL III. Recurrent disease after limited parathyroidectomy for sporadic primary hyperparathyroidism. J Am Coll Surg. 2004;199:849-853.
79. Gauger PG, Mullan MH, Thompson NW, Doherty GM, Matz KA, England BG. An alternative analysis of intraoperative parathyroid hormone data may improve the ability to detect multiglandular disease. Arch Surg. 2004;139:164-169.
80. Gawande AA, Monchik JM, Abbruzzese TA, Iannuccilli JD, Ibrahim SI, Moore FD Jr. Reassessment of parathyroid hormone monitoring during parathyroidectomy for primary hyperparathyroidism after 2 preoperative localization studies. Arch Surg. 2006;141:381-384.
81. Jacobson SR, van Heerden JA, Farley DR, et al. Focused cervical exploration for primary hyperparathyroidism without intraoperative parathyroid hormone monitoring or use of the gamma probe. World J Surg. 2004;28:1127-1131.
82. Irvin GL III. American Association of Endocrine Surgeons. Presidential address: chasin' hormones. Surgery. 1999;126:993-997.
83. Carneiro-Pla DM, Solorzano CC, Irvin GL III. Consequences of targeted parathyroidectomy guided by localization studies without intraoperative parathyroid hormone monitoring. J Am Coll Surg. 2006;202:715-722.
84. Mandell DL, Genden EM, Mechanick JL, Bergman DA, Diamond EJ, Urken ML. The influence of intraoperative parathyroid hormone monitoring on the surgical management of hyperparathyroidism. Arch Otolaryngol Head Neck Surg. 2001;127:821-827
85. Kaczirek K, Prager G, Riss P, et al. Novel parathyroid hormone (1-84) assay as basis for parathyroid hormone monitoring in renal hyperparathyroidism. Arch Surg. 2006;141:129-134.
86. Matsuoka S, Tominaga Y, Sato T, et al. QuiCk-IntraOperative Bio-Intact PTH assay at parathyroidectomy for secondary hyperparathyroidism. World J Surg. 2007;31:824-831.
87. Tonelli F, Spini S, Tomassi M, et al. Intraoperative parathormone measurement in patients with multiple endocrine neoplasia type I syndrome and hyperparathyroidism. World J Surg. 2000;24:556-562; discussion 562-563.